01.07.11
Cambrex Zenara is supplying product for Johnson & Johnson Ltd.'s launch of smoking cessation drug Nicorette in India. The Nicorette product is being manufactured and packaged by Cambrex Zenara in its Hyderabad, India facility.
"Nicotine Replacement Therapeutics represent an important part of our product portfolio," said Steven M. Klosk, president and chief executive officer of Cambrex. "It is estimated that India has over 270 million tobacco users, second only to China, and we are proud to supply product for Johnson & Johnson's launch of Nicorette in this market."
Ashok Narasimhan, president of Cambrex Zenara said, "Being selected by Johnson & Johnson as their manufacturing partner is a testament to Cambrex Zenara's ability to supply product for a well-known brand to a very large market. This demonstrates our commitment to provide high quality, affordable solutions for smoking cessation."
"Nicotine Replacement Therapeutics represent an important part of our product portfolio," said Steven M. Klosk, president and chief executive officer of Cambrex. "It is estimated that India has over 270 million tobacco users, second only to China, and we are proud to supply product for Johnson & Johnson's launch of Nicorette in this market."
Ashok Narasimhan, president of Cambrex Zenara said, "Being selected by Johnson & Johnson as their manufacturing partner is a testament to Cambrex Zenara's ability to supply product for a well-known brand to a very large market. This demonstrates our commitment to provide high quality, affordable solutions for smoking cessation."